VANCOUVER, June 3 /PRNewswire-FirstCall/ -- Editors are advised to disregard TO249, "TEST - Jay 14 - Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor", transmitted at 00:13 today, but dated May 28. This story was transmitted by CNW Group Ltd. in error and should not be used. CONTACT: CNW Group Ltd., 416-863-2130 DATASOURCE: Cardiome Pharma Corp. CONTACT: CNW Group Ltd., 416-863-2130

Copyright